Does Preventive Health Care Actually Save You Money? An Honest Look

The short answer: at a population level, yes, convincingly. At an individual level, it's more nuanced than the marketing usually admits — and worth being honest about, especially in Switzerland, where comprehensive screening panels are typically an out-of-pocket decision, not an insurance benefit.

The population-level evidence is strong

A 2023 peer-reviewed study in BMC Health Services Research, led by health economists at the University of Chicago and University of Michigan, modeled the impact of breast, cervical, colorectal, and lung cancer screening in the U.S. from 1996 to 2020. Their estimate: at least 12 million additional life-years and at least $6.5 trillion in economic value from screenings already performed — and that figure excludes the direct medical savings from treating cancer at an earlier, cheaper stage. It's worth noting the study was funded by Grail LLC, a company that develops multi-cancer screening tests, so the incentive to find a positive result exists; the underlying methodology was still peer-reviewed and the USPSTF screening recommendations it models are independently set.

On cardiovascular disease specifically, the U.S. CDC reports that heart disease already costs the health system more than $168 billion in care and medication in 2021–2022 alone — costs concentrated in the acute and chronic-management stages that early risk-factor detection and control are designed to reduce or delay.

Why the individual math is less clean

Here's the honest caveat: most people who get screened do not have the condition being screened for. That's the intended design — screening is a population strategy, not a guarantee of individual savings. For any one person, a comprehensive panel is a cost today in exchange for a probability-weighted reduction in future risk, not a certainty of financial return. The value is real, but it's closer to insurance than investment: you're not betting you'll "win," you're managing downside risk.

Where the individual case is strongest is in catching problems that are cheap to manage early and expensive to manage late: elevated blood pressure caught before a stroke, a rising HbA1c caught before insulin dependence and complications, a lipid abnormality caught before a cardiac event. These are the scenarios preventive testing is built around.

The Swiss context — an honest note on insurance

In Switzerland, mandatory basic insurance (LAMal/KVG) covers a defined, narrower set of check-ups tied to specific age and risk criteria set by federal law — it does not typically cover comprehensive, elective biomarker panels of the kind Aeonix offers. That means the cost of a panel like ours is usually an out-of-pocket wellness investment, not a reimbursed medical expense. We think that's worth saying plainly rather than implying otherwise: you're paying for information and peace of mind now, weighed against a reduced probability of a very expensive, very disruptive diagnosis later.